Navigation Links
ImmusanT Relocates Offices to State-of-the-Art Innovation Facility
Date:8/16/2012

CAMBRIDGE, Mass., Aug. 16, 2012 /PRNewswire/ -- ImmusanT, Inc. announced today that it has relocated its operations to One Kendall Square, a 676,000-square-foot, mixed-use campus in the heart of Cambridge. The facility allows ImmusanT to establish a state-of-the-art lab for conducting immunologic assays to support its development efforts and clinical trials in celiac disease and other autoimmune diseases.

One Kendall Square is a nine-building campus located just minutes from Massachusetts Institute of Technology offering office, laboratory and retail space. Building 200 offers new incubator space and provides ImmusanT with its own lab facility as well as shared services that allow the company to remain capital efficient as it advances its development and discovery programs. The ImmusanT lab will specialize in a variety of high-throughput immune monitoring techniques, and the accompanying office space will accommodate the company's small executive team.

"We spent a considerable amount of time assessing options to allocate our resources toward our offices and lab. At One Kendall Square we're part of a thriving hub of innovation and it's a great environment in which to build our business," said Leslie Williams, President and CEO of ImmusanT. "Our new immune monitoring lab will allow us to sustain and better monitor critical aspects of our Nexvax2® development program and we feel it is vital in ensuring efficiency, quality and retention of expertise in-house."

ImmusanT worked directly with its broker, T3 Advisors to complete the lease agreement with The Beal Companies.

About ImmusanT, Inc.
ImmusanT is a privately-held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The company is developing Nexvax2®, a therapeutic vaccine for celiac disease, and a companion diagnostic and monitoring tool to improve celiac disease management. ImmusanT's targeted immunotherapy discovery platform can be applied to a variety of epitope-specific autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners. More information can be found at www.ImmusanT.com.


'/>"/>
SOURCE ImmusanT, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ultragenyx Relocates Company Headquarters to Support Operational Expansion
2. Forum Extended Care Services Announces Plans to Move to Larger, State-Of-the-art Facility
3. Specialty Silicone Fabricators Inaugurates New State-of-the-Art Facility in Paso Robles
4. Center for Medicare & Medicaid Innovation Awards $19 Million Grant to Develop Oncology Medical Home Model
5. Elekta to Showcase Revolutionary Agility Beam-shaping Innovation at Radiation Physics Annual Meeting
6. Young Innovations, Inc. Board of Directors Declares Quarterly Dividend
7. Sanofi US Launches Collaborate Activate Innovation Challenge
8. Joslin Diabetes Center Convenes Leaders in Diabetes Prevention, Treatment, Payment, Education and Research at Diabetes Innovation 2012
9. Siemens Unveils New Solutions and Latest Innovations at AACC 2012
10. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
11. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
Breaking Medicine News(10 mins):